Belgian Study Examines Ilama Blood Antibody for Covid-19 Medicine
Breakthrough after breakthrough emerged to find corona virus infection therapy (Covid-19), one of which was in an uproar was with eucalyptus which was considered to have potential as an antivirus.
In addition, other studies in Belgium recently tried to isolate antibodies from the body of ilama (Lama glama) to treat corona virus patients. According to Professor Xavier Saelens of the Flemish Institute of Biotechnology (VIB), if successful this is not the first time that science has been useful in medical science.
“There are drugs on the market that come from antibodies in the blood of ilama,” Saelens said, quoting from Medical Xpress.
Previously known antibodies in caplacizumab are used for the treatment of disorders of blood platelets or Thrombocytopenic purpura. Now Saelens and the team are working with a team from the University of Texas Austin to find a major breakthrough in the search for corona drugs.
The research team also involved a female ilama named Winter. Winter is injected with proteins from the corona virus surface. His body reacts by developing antibodies.
“Ilama has an immune response to this protein. Our goal is to produce an antiviral treatment that will involve giving antibodies directly to the patient,” explained VIB researcher Dorien De Vlieger.
They say testing in patients can begin before the end of the year.
Although it looks promising, this research clearly requires a long and expensive time. Even research doesn’t always produce results. In addition, not all researchers can access this camel-like animal.
Research related to this antibody ilama is not new. Launching from Harvard Medicine, ilama, alpaca, camels, and other camel family members produce antibody classes that allow scientists to determine the structure of proteins that are impossible to study in the body, understand how those proteins do not function in diseases, and design effective new drugs to them.
Responding to this, internal medicine specialist and IDI member Prof. Zubairi Djoerban revealed that this might happen.
“Yes, it’s possible, but there is a tap, that’s another species so if transferred to humans it must use a long process,” he said when contacted by CNNIndonesia.com, Thursday (5/14).
“So, in principle, we can’t get a part of animal blood for us, that’s the reaction will be very dangerous, even if we can choose the antibodies that are isolated, it needs a more complicated process.
However, there are some disadvantages found when using ilama antibodies.
One of them is access to animals, a high price and a long test time.
At that time research with antibody ilama and other camel families were replaced with yeast. A team of structural biologists from the HMS Department of Biological Chemistry and Molecular Pharmacology and from the University of California developed a specially engineered yeast bottle.
The yeast method can be done in a test tube in a laboratory. Yeast is considered to have a higher success rate and completion time is faster than ilama vaccination.
The HMS research team has created a library of 500 million camel antibodies using yeast cells. Each yeast cell has a slightly different nanobody tethered to its surface.
But instead of using antibodies from different species, Zubairi revealed the use of antibodies from humans themselves are considered more effective. With the same species, the risk is considered to be smaller.
“If the plasma convalecent (periodic healing after the patient is infected) the patient’s plasma has recovered the process is simpler and faster to use certain tools. Blood from the blood vessels of patients who have recovered is inserted into the device then the plasma is separated and other cells returned to the patient.”